263 related articles for article (PubMed ID: 35908759)
1. Medicinal cannabis for the treatment of anxiety disorders.
Berger M; Amminger GP; McGregor IS
Aust J Gen Pract; 2022 Aug; 51(8):586-592. PubMed ID: 35908759
[TBL] [Abstract][Full Text] [Related]
2. Differences in prescribed medicinal cannabis use by cannabinoid product composition: Findings from the cannabis as medicine survey 2020 (CAMS-20) Australia-wide study.
Trevitt BT; Bailey S; Mills L; Arkell TR; Suraev A; McGregor IS; Lintzeris N
PLoS One; 2024; 19(2):e0297092. PubMed ID: 38354169
[TBL] [Abstract][Full Text] [Related]
3. A primer on medicinal cannabis safety and potential adverse effects.
Arnold JC
Aust J Gen Pract; 2021 Jun; 50(6):345-350. PubMed ID: 34059837
[TBL] [Abstract][Full Text] [Related]
4. Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.
Sarris J; Sinclair J; Karamacoska D; Davidson M; Firth J
BMC Psychiatry; 2020 Jan; 20(1):24. PubMed ID: 31948424
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
6. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG
Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352
[TBL] [Abstract][Full Text] [Related]
7. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
8. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Cannabis, Cannabidiol, and Cannabinoid-Based Pharmaceuticals.
Legare CA; Raup-Konsavage WM; Vrana KE
Pharmacology; 2022; 107(3-4):131-149. PubMed ID: 35093949
[TBL] [Abstract][Full Text] [Related]
10. Mapping cannabis potency in medical and recreational programs in the United States.
Cash MC; Cunnane K; Fan C; Romero-Sandoval EA
PLoS One; 2020; 15(3):e0230167. PubMed ID: 32214334
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol in medical marijuana: Research vistas and potential opportunities.
Rong C; Lee Y; Carmona NE; Cha DS; Ragguett RM; Rosenblat JD; Mansur RB; Ho RC; McIntyre RS
Pharmacol Res; 2017 Jul; 121():213-218. PubMed ID: 28501518
[TBL] [Abstract][Full Text] [Related]
13. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties.
Sharpe L; Sinclair J; Kramer A; de Manincor M; Sarris J
J Transl Med; 2020 Oct; 18(1):374. PubMed ID: 33008420
[TBL] [Abstract][Full Text] [Related]
14. Effect of prior foot shock stress and Δ
Rock EM; Limebeer CL; Petrie GN; Williams LA; Mechoulam R; Parker LA
Psychopharmacology (Berl); 2017 Jul; 234(14):2207-2217. PubMed ID: 28424834
[TBL] [Abstract][Full Text] [Related]
15. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.
Baron EP; Lucas P; Eades J; Hogue O
J Headache Pain; 2018 May; 19(1):37. PubMed ID: 29797104
[TBL] [Abstract][Full Text] [Related]
16. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use.
Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP
Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860
[TBL] [Abstract][Full Text] [Related]
17. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
Szaflarski JP; Bebin EM
Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
[TBL] [Abstract][Full Text] [Related]
18. Cannabis update: Anxiety disorders and post-traumatic stress disorder.
Haycraft AL
J Am Assoc Nurse Pract; 2023 May; 35(5):276-280. PubMed ID: 37000126
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
20. Does medicinal cannabis affect depression, anxiety, and stress in people with cancer? A systematic review and meta-analysis of intervention studies.
Crichton M; Dissanayaka T; Marx W; Gamage E; Travica N; Bowers A; Isenring E; Yates P; Marshall S
Maturitas; 2024 Jun; 184():107941. PubMed ID: 38430618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
